Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1007-1015

  Cesaro, Annabelle ^a,b   Bettoni, Romain Roth Dit ^a,b   Lascols, Christine ^a,b   Mérens, Audrey ^c,d   Soussy, Claude James ^a,b   Cambau, Emmanuelle ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SERVICE D ENDOCRINOLOGIE   (France)

^d Centre d'Epidémiologie et de Santé   (France)

Author keywords

Ciprofloxacin; Gyrase; Moxifloxacin; QRDR; Quinolones

Indexed keywords

ASPARAGINE; ASPARTIC ACID; BACTERIAL PROTEIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) B; MOXIFLOXACIN; NALIDIXIC ACID; PROLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CONJUGATION; CODON; CONTROLLED STUDY; DNA SEQUENCE; ESCHERICHIA COLI; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; CODON; DNA TOPOISOMERASES, TYPE II, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; PLASMIDS; QUINOLONES; SELECTION (GENETICS);

EID: 42149122626     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn077     Document Type: Article

References (54)

1. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: S120-6.
2. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-9.
3. Robicsek A, Strahilevitz J, Jacoby GA et al. Fluoroquinollone-modifying enzyme: A new adaptation of a commom aminoglycoside acetyltransferase. Nat Med 2006; 12: 83-8.
4. Perichon B, Courvalin P, Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli, Antimicrob Agents Chemother 2007; 51: 2464-9.
5. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: 20-51.
6. Hooper D. Mechanisms of quinolone resistance. In: Hooper D. Rubinstein E, eds. Quinolone Atimicrobiol Agents. Washington, DC: ASM Press, 2003; 41-67.
7. Komp Lindgren P, Marcusson LL, Sandvang D et al. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 2005; 49: 2343-51.
8. Yoshida H, Bogaki M, Nakamura M et al. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia Coli. Antimicrob Agents Chemother 1990; 34: 1271-2.
9. Yoshida H, Bogaki M, Nakamura M et al. Quinolone resistance-determining region in The DNA gyrase gyrB gene of Escherichia cali. Antimicrob Agent Chemother 1991; 35: 1647-50.
10. Heisig P, Tschomy R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284-91.
11. Hopkins KL, Davies RH, Threifall EJ. Machanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments. Int J Antimicrob Agents 2005; 25: 358-73.
12. Bachoual R, Tankovic J, Soussy CJ. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli: Microb Drug Resist 1998; 4: 271-6.
13. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40: 879-85.
14. Kumagai Y, Kato JI, Hoshino K. et al. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother 1996; 40: 710-4.
15. Breines DM, Ouabdesselam S, Ng EY et al. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother 1997; 41: 176-9.
16. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002; 99: 5638-42.
17. Hata M, Suzuki M, Matsumoto M et al. Cloning of a novel gene for quinolone resistance from a transferable plasmid ip Shigella flexneri 2b. Antimicrob Agents Chemother 2005: 49: 801-3.
18. Jacoby GA, Walsh KE, Mills DM et al. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother 2006; 50: 1178-82.
19. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6; 629-40.
20. Pai H, Seo MR, Choi TY. Association of QnrB determinants and production of extended-spectrum β-lactamases or plasmid-mediated AmpC β-lactamases in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 2007; 51: 366-8.
21. Montero C, Mateu G, Rodriguez R et al. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob Agents Chemother 2001; 45 3387-92.
22. Parks WM, Bottrill AR, Pierrat OA et al. The action of the bacterial toxin, microcin bB7, on DNA gyrase. Biochimie 2007; 89: 500-7.
23. Vatting MW, Hegde SS, Fajardo JE et al. Pentapeptide repeat proteins. Biochemistry 2006; 45: 1-10.
24. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 2005; 49: 118-25.
25. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother 2005; 49: 3050-2.
26. Martinez-Martinez L, Pascual A, Garcia I et al. Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother 2003; 51: 1037-9.
27. Lascols C, Robert J, Cattoir V et al. Type II topoisomerase mutations in clinical isolates of Enterobacter cloacae and other enterobacterial species harbouring the qnrA gene. Int J Antimicrob Agents 2007; 29: 402-9.
28. Wang M, Sahm DF, Jacoby GA et al. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004; 48: 1295-9.
29. Kehrenberg C, de Jong A, Friederichs S et al. Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations. J Antimicrob Chemother 2007; 59: 886-92.
30. Cambau E, Lascols C, Sougakoff W et al. Occurrence of qnrA positive clinical isolates in French teaching hospitals during 2002-2005. Clin Microbiol Infect 2006; 12: 1013-20.
31. Robicsek A, Strahilevitz J, Sahm DF et al. Qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 2006; 50: 2872-4.
32. Blondeau JM, Zhao X, Hansen G et al. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433-8.
33. Jacoby GA, Chow N, Waites KB. Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 2003; 47: 559-62.
34. Gilbert DN, Kohlhepp SJ, Slama KA et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001; 45: 883-92.
35. Hooper DC, Wolfson JS, Ng EY et al. Mechanisms of action of and resistance to ciprofloxacin. Am J Med 1987; 82: 12-20.
36. Olofsson SK, Marcusson LL, Komp Lindgren P et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: Relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 2006; 57: 1116-21.
37. Nakamura S, Nakamura M, Kojima T et al. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coll. Antimicrob Agents Chemother 1989; 33: 254-5.
38. Tavio MM, Vila J, Ruiz J et al. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coll isolates. J Antimicrob Chemother 1999; 44: 735-42.
39. Yu X, Susa M, Knabbe C et al. Development and validation of a diagnostic DNA microarray to detect quinolone-resistant Escherichia coli among clinical isolates. J Clin Microbiol 2004; 42: 4083-91.
40. Cambau E, Bordon F, Collatz E et al. Novel gyrA point mutation in a stain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother 1993; 37: 1247-52.
41. Truong QC, Nguyen Van JC, Shlaes D et al. A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob Agents Chemother 1997; 41: 85-90.
42. Blanc-Potard AB, Labesse G, Figueroa-Bossi N et al. Mutation at the 'exit gate' of the Salmonella gyrase A subunit suppresses a defect in the gyrase B subunit. J Bacteriol 2005; 187: 6841-4.
43. Corbett K, Berger J. Structure, molecular mechanisms and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 2004; 33: 95-118.
44. Eggertsson G, Soll, D. Transfer ribonucleic acid-mediated suppression of termination codons in Escherichia coli. Microbiol Rev. 1988; 52 354-74.
45. Belin D. Why are suppressors of amber mutations so frequent among Escherichia coli K-12 strains? A plausible explanation for a long-lasting puzzle. Genetics 2003; 165: 455-6.
46. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2: 530-8.
47. Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobactedaceae. J Antimicrob Chemother 2005; 56: 463-9.
48. Wang, M, Sahm DF, Jacoby GA et al. Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother 2004; 48: 1400- 1.
49. Hyle EP, Lipworth AD, Zaolitis TE et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: Variability by site of infection. Arch Intern Med 2005; 165: 1375-80.
50. Corkill JE, Anson JJ, Hart CA. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. J. Antimicrob Chemother 2005; 56: 1115-7.
51. Chenia HY, Pillay B, Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother 2006; 58: 1274-8.
52. Robicsek A, Sahm DF, Strahilevitz J et al. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob Agents Chemother 2005; 49: 3001-3.
53. Robert J, Cambau E, Grenet K et al. Trends in quinolone susceptibility of Enterobacteriaceae among in patients of a large university hospital: 1992-98. Clin Miciobiol Infect 2001 7: 553-61.
54. Park YJ. Yu JK, Lee S et al. Prevalence and diversity of qnr alleles in AmpC-producing Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundil and Serratia marcescens, a multicentre study from Korea. J Antimicrob Chemother 2007; 60 868-71.